A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology.
Initiating coverage, Jarden analysts Christian Bell and Adrian Allbon set a 12-month target price on
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
